Скачать или смотреть Results of the Phase II CART19-BE-02 trial of var-cel (ARI-0001) in patients with R/R B-ALL

Valentín Ortiz-Maldonado, MD, Hospital Clinic Barcelona, Barcelona, Spain, discusses the Phase II multicenter CART19-BE-02 trial (NCT04778579), which investigated varnimcabtagene autoleucel (var-cel; ARI-0001) in adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), highlighting the trial's stringent measurable residual disease (MRD)-based primary endpoint and fractionated adaptive interpatient dosing strategy. Dr Ortiz-Maldonado notes that the primary endpoint was met, with the majority of patients achieving MRD-negative complete remission (CR), and the durability of responses was encouraging. This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting, held in Palma de Mallorca, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.